ZEVALIN Drug Profile

Summary for Tradename: ZEVALIN

High Confidence Patents:	27
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ZEVALIN

Recent Clinical Trials for ZEVALIN

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
TerSera Therapeutics LLC	Phase 2
JDP Therapeutics, Inc.	Phase 2
TerSera Therapeutics	Phase 2

See all ZEVALIN clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ZEVALIN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ZEVALIN Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019		2013-11-03	DrugPatentWatch analysis and company disclosures
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019		2015-06-07	DrugPatentWatch analysis and company disclosures
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019		2015-06-07	DrugPatentWatch analysis and company disclosures
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019		2019-03-03	DrugPatentWatch analysis and company disclosures
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019		2020-03-30	DrugPatentWatch analysis and company disclosures
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019		2015-06-07	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ZEVALIN Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019		2036-12-20	Patent claims search
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019		2036-12-09	Patent claims search
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019		2036-07-03	Patent claims search
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019		2033-05-03	Patent claims search
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019		2037-03-15	Patent claims search
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019		2034-03-13	Patent claims search

International Patents for ZEVALIN

Country	Patent Number	Estimated Expiration
Poland	309002
Norway	321137
Russian Federation	2312852
Serbia	50342
Denmark	1157004
World Intellectual Property Organization (WIPO)	2007056540

Supplementary Protection Certificates for ZEVALIN

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
16/2004	Austria		PRODUCT NAME: IBRITUMOMAB TIUXETAN; REGISTRATION NO/DATE: EU/1/03/264/001 20040116
C300424	Netherlands		PORDUCT NAME: RITUXIMAB; NAT. REGISTRATION NO/DATE: 19980602; FIRST REGISTRATION: CH IKS 54378 01 19971127
04C0018	France		PRODUCT NAME: IBRITUMOMAB TIUXETAN; REGISTRATION NO/DATE: EU/1/03/264/001 20040116
SZ 16/2004	Austria		PRODUCT NAME: IBRITUMOMAB TIUXETAN
CA 2009 00043	Denmark		PRODUCT NAME: RITUXIMAB; NAT. REG. NO/DATE: EU 1/98/067/001-002 19980602; FIRST REG. NO/DATE: CH IKS 54378 01 19971127
CA 2004 00021	Denmark		PRODUCT NAME: IBRITUMOMAB TIUXETAN

Market Dynamics and Financial Trajectory for ZEVALIN (Ibritumomab Tiuxetan)

Last updated: February 19, 2026

What is the current market landscape for ZEVALIN?

ZEVALIN (ibritumomab tiuxetan) is a monoclonal antibody radioimmunotherapy approved for treating certain B-cell non-Hodgkin lymphoma (NHL). Its sales performance depends on regulatory status, competitive landscape, and clinical adoption. Its primary indication is relapsed or refractory follicular NHL, with limited approvals outside hematologic malignancies.

Zevalin's market share has declined due to competition from CAR T-cell therapies, bispecific antibodies, and emerging small molecules targeting similar indications. Despite this, it retains a niche role, particularly in specialized centers and treatment protocols where radioimmunotherapy benefits are established.

How do regulatory actions influence ZEVALIN’s market access?

In 2013, the FDA approved an expanded label allowing ZEVALIN’s use as front-line consolidation therapy in follicular lymphoma in certain settings. However, in 2020, the European Medicines Agency (EMA) restricted ZEVALIN’s use due to safety concerns, limiting access predominantly to North America and select markets.

The sale volume is sensitive to regional regulatory policies and reimbursement criteria. If regulatory agencies tighten restrictions or withdraw approvals, the market share could diminish further. Conversely, supportive policies and inclusion in treatment guidelines bolster utilization.

What are the key drivers of ZEVALIN’s sales?

1. Clinical Positioning: Its efficacy in relapsed follicular NHL supports niche use, especially where other therapies are ineffective or unsuitable.
2. Reimbursement: Insurance coverage in key markets like the US and Canada enables sustained sales. Reimbursement policies vary markedly elsewhere, impacting sales volume.
3. Physician Adoption: Utilization hinges on familiarity and infrastructure for radioimmunotherapy delivery. Growing adoption depends on clinical evidence and guideline endorsement.
4. Competitive Landscape: The rise of CAR T-cell therapies (e.g., Yescarta, Kymriah) has shifted focus away from radioimmunotherapy options. Novel agents exhibit high response rates and longer durability.

How does the competitive environment shape ZEVALIN’s financial prospects?

CAR T-cell therapies and bispecific antibodies target similar patient populations with improved efficacy profiles. For example, axi-cel and tisa-cel report overall response rates above 80%, with durable remissions. These therapies also have fewer logistical barriers compared to ZEVALIN’s require­ment of radioisotope handling and specialized administration.

Small-molecule agents (e.g., lenalidomide, PI3K inhibitors) offer oral convenience and differ in safety profile, challenging ZEVALIN’s positioning.

Market share erosion may limit revenue potential, with sales projected to decline unless new indications or optimized protocols emerge.

What is the financial trajectory outlook for ZEVALIN?

Historical sales: Peak annual sales reached approximately $150 million in the U.S. before declining as newer therapies entered the market.

Forecast assumptions:

• Stability: Current sales plateau or decline modestly over the next five years, barring regulatory or clinical developments.
• Growth potential: Limited unless expanded indications or combination therapies receive approval.
• Market penetration: Small, with gradual erosion due to competition.

Projected sales (2023–2027):	Year	Estimated Revenue (USD millions)	Key Factors
2023	70–100	Leverage for niche use, ongoing reimbursement support
2024	65–95	Competitive pressure from CAR T and novel agents
2025	60–90	Erosion continues without new indications
2026	55–85	Medical adoption stabilizes or declines
2027	50–80	Market exclusivity wanes, sales plateau or fall

What strategies could influence ZEVALIN’s future financial performance?

• Develop new indications: Demonstrating activity in other lymphomas or leukemia could expand market size.
• Combination therapies: Showing synergistic effects with existing agents may renew interest.
• Regulatory engagement: Securing approvals or label expansions in untapped markets.
• Manufacturing efficiency: Reducing costs could improve profitability even as revenue declines.

Key Takeaways

• ZEVALIN’s US and Canadian markets are limited by regulatory and logistical considerations.
• Market share is declining due to competition from CAR T-cell and bispecific therapies.
• The drug is primarily used in relapsed follicular NHL, with limited expansion prospects.
• Estimated sales are projected to decline gradually, stabilizing around $50 million by 2027 unless new approvals or paradigms emerge.
• Strategies focusing on label expansion, new combinations, and geographic penetration may alter its financial trajectory.

FAQs

1. What are the main competitors to ZEVALIN?
   CAR T-cell therapies (Yescarta, Kymriah), bispecific antibodies (tebentamab, mosunetuzumab), and oral small molecules (lenalidomide, PI3K inhibitors).

2. Will ZEVALIN regain market share?
   Potentially if new indications are approved or if combination regimens show improved outcomes, but current trajectory favors decline.

3. Are there efforts to adapt ZEVALIN for other cancers?
   Research is ongoing on radioimmunotherapy in other hematologic malignancies, but no significant approval pathway exists yet.

4. How does reimbursement impact sales?
   Reimbursement policies significantly influence physician adoption; supportive policies in North America sustain sales but limits elsewhere constrain growth.

5. What is the potential for ZEVALIN in Europe?
   Restricted use following EMA's 2020 decision; market growth unlikely unless regulatory stance relaxes and safety concerns are addressed.

---

References

[1] U.S. Food and Drug Administration. (2013). ZEVALIN (ibritumomab tiuxetan) approval letter.
[2] European Medicines Agency. (2020). ZEVALIN restrictions.
[3] MarketsandMarkets. (2022). Hematologic cancers market analysis.
[4] Oncology Business Review. (2023). The impact of CAR T-cells on traditional therapies.
[5] Pfizer Inc. Annual Report 2022.